BioAtla raises $189m for IPO

BioAtla Inc, a developer of therapeutics for treating solid tumor cancer, has raised $189 million for its IPO after pricing its 10.5 million shares at $18 per share.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this